Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Phase 1

Terminated

Conditions: Renal Cell Cancer
Squamous Cell Carcinoma
Sarcoma
Colorectal Cancer
Bladder Cancer
Head and Neck Cancer
Melanoma
Non-Small-Cell Lung Cancer
Hepatocellular Cancer
Ovarian Cancer

Interventions: Biological: PF-07263689
Biological: Sasanlimab

First Posted Date: 2021-09-29

Last Posted Date: 2024-04-12

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT05061537

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
CUMC Research Pharmacy, New York, New York, United States

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Recifercept

First Posted Date: 2021-09-29

Last Posted Date: 2023-04-18

Lead Sponsor: Pfizer

Registration Number: NCT05061277

Locations: 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3

Active, not recruiting

Conditions: Advanced Malignancies
NSCLC
Ovarian Cancer
Urothelial Cancer
Solid Tumors

Interventions: Drug: Avelumab
Drug: CMP 001
Drug: Lorlatanib
Drug: Talazoparib
Drug: Pemetrexed
Drug: Axitinib
Drug: Utomilumab
Drug: PF04518600

First Posted Date: 2021-09-28

Last Posted Date: 2024-11-13

Lead Sponsor: Pfizer

Target Recruit Count: 67

Registration Number: NCT05059522

Locations: 🇺🇸
Highlands Oncology Group, PA, Springdale, Arkansas, United States
🇷🇺
Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary", Omsk, Omskaya Oblast', Russian Federation
🇺🇸
MSK Monmouth, Middletown, New Jersey, United States

and more 66 locations

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza

Phase 1

Completed

Conditions: Influenza, Human

Interventions: Biological: mIRV
Biological: bIRV AB
Biological: qIRV
Biological: QIV
Biological: bIRV AA
Biological: bIRV BB

First Posted Date: 2021-09-22

Last Posted Date: 2024-03-12

Lead Sponsor: Pfizer

Target Recruit Count: 1158

Registration Number: NCT05052697

Locations: 🇺🇸
NYU Langone Cardiology Associates, Delray Beach, Florida, United States
🇺🇸
Robert B. Pritt, DO, Fort Myers, Florida, United States
🇺🇸
Orange County Research Center, Tustin, California, United States

and more 89 locations

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07304814

First Posted Date: 2021-09-20

Last Posted Date: 2022-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 5

Registration Number: NCT05050682

Locations: 🇺🇸
Labcorp Clinical Research Unit, Madison, Wisconsin, United States

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: PF-07321332
Drug: Placebo for PF-07321332
Drug: Placebo for Ritonavir
Drug: Ritonavir

First Posted Date: 2021-09-17

Last Posted Date: 2023-05-06

Lead Sponsor: Pfizer

Target Recruit Count: 2954

Registration Number: NCT05047601

Locations: 🇺🇸
Accellacare, Ames, Iowa, United States
🇨🇴
Clinica de la Costa LTDA., Barranquilla, Atlantico, Colombia
🇭🇺
Medifarma-98 Kft., Nyiregyhaza, Hungary

and more 165 locations

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

Active, not recruiting

Conditions: Migraine

Interventions: Other: Rimegepant
Other: Not taking Rimegepant

First Posted Date: 2021-09-16

Last Posted Date: 2025-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 780

Registration Number: NCT05046613

Locations: 🇺🇸
Pfizer, New York, New York, United States

European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Palbociclib + aromatase inhibitor
Drug: Aromatase inhibitor

First Posted Date: 2021-09-14

Last Posted Date: 2024-03-27

Lead Sponsor: Pfizer

Target Recruit Count: 1939

Registration Number: NCT05043506

Locations: 🇸🇪
Örebro University Hospital, Örebro, Sweden
🇩🇪
Medizinische Studiengesellschaft NORD-WEST GmbH, Westerstede, Germany
🇩🇪
Ruppiner Kliniken GmbH, Neuruppin, Ostprignitz-ruppin, Germany

and more 61 locations

A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: ritlecitinib

First Posted Date: 2021-09-10

Last Posted Date: 2023-08-21

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05040295

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France

Active, not recruiting

Conditions: Atrial Fibrillation

Interventions: Drug: Apixaban
Drug: Rivaroxaban
Drug: Dabigatran
Drug: Vitamin K antagonist (VKA)

First Posted Date: 2021-09-09

Last Posted Date: 2025-04-16

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05038228

Locations: 🇬🇧
Pfizer Investigator, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy